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TIle .ffect 01 dill.reDt .protbUa .ppllcatloDS Oll h.-
moetatlc eb ... _ ud blood. product requlreme.t. In 
ortbotopic liver trauplautatloD w .. mv..tilated lD • 
proepecUve. open, ud randomized Iludy, 
Prom November 1989 to Jtme 1990. 18 patt.DU re. 
oelved aprotlalD ... bo1u 01 0.0 MW. k.lJIkrelD. iAac-
U •• tor uaJ.ts (KIU) OD tiu'ee OOCMloaa lD. the coune 0' 
aD OLT, .. urea 10 otIMr paU.DU were tr..ted with 
OODtblUOUII .protbdD lDtuDOD 010.1-0 •• MW. KIU/hr. 
BeloN -.4 alter repert.loD 01 the p-aft liver. mpa. 01 
JonerlIbrlDolyala, m-.ed by Ihn>mhe~.pby, 
weN lifD.lfleutly lower la tu lDluloD IP'OUP. T ........ 
type plumlaoa:eD ac:t1vator (t·PA) activity lacreued 
du:rIJaC lbe aallepatie phue but to • lipiIleudy l ... r 
e .. teDt lD. lbe batuiOD lP'Oup. Blood. produci requil'e. 
lIMati du..rbla OLT were teDdeDtlOtWy hleber ba tbe 
bolllll lJ'Oup but DOt eJca1ftcaaily 10. Bowever, th. UM 
01 packed ncl blood ceu. ... QnUleaatly 10wer iD. tu 
po.&operaUve period. wbereu tlMre w .. llO .tcaHIca.at 
dlttereDCe in treü trosen pluma reqlllrelDent. bMween 
tIM two II'OUPI. 
AU 38 patieJ:lt. have aurvived, ud oDly ODe WOJDaJl 01 
Melh ~p reqa.ired retramplaDtatloD. due to Mvere 
hoet-venu.paft reactio .... 
l'urthermore. we mveet.lp.ted. the pertaaate 01 the 
araft Uver La both ll'Ou,. ud deteeted ~ 01 a de-
o ........ t-PA releuelD the bafu;ioD IJ'OUp. 
Our renlt. demoutrate aa advaataae 01 aprotlain 
liven U coDtmuoa. lDtUaloD over bola. appUcaUoD lD 
OLT. 
In OLT, hyperfibrillolyail h.u been recopized .. an impor-
tant ClUM of intra- and poet.operative bleedin& (1-.. 1), intluenc-
inI both the ahort- and lon,-term outcome (4, 6). PreviOUI 
inVflltigationa have indicated that hyperfibrinolyaia ia due to 
an increue olüuue-type pwminopn activator (t-PA)· activ-
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ity (1, 3) and a concomitant increue of urokinue-type plu-
minogen aetivator (u-PA) activity (1) . 
Aprotinin (Traaylol, Bayer, Leverkueen, Germany), a par-
enterally applied proteinue inhibitor from bovine lune (6-8), 
inhibite plumin, kallikrein, tryp&in, ud to IOme enent human 
urokinaM (7). Tb. toxicity of aprotinin iI ennmely low (7), 
ud even hieb. doIOI are well tolerated (6, 9). AI randomiJed 
et:udi. in cardiac l\lI"Pry bave demonatrated ailnificantly re-
ducecl tranafuaion requirementa when aprotinin w ... dmin; •• 
tered durine lurpry (10, ll ), we teated ita application in 
patienta undergoing OLT. Boh" application of 0.6 MüI. kaIli· 
krein inactivator unita (KIU) aprotinin liven three timet dur-
lnJ OLT led. to reductiona in blood product requiremant and in 
the increue olt·PA activity (1 ) .. compared with tbe reporta 
of other inveetipton (2, 3, 12). Nevertbeleu, thrombeluto-
pphy (TEG) ahowed aipu oi hyperfibrinoly.i. in moo of the 
OLT., in apite ol aprotinin bolua application. 
In the prMOnt etudy, we have inveetipted tbe efrett of two 
different aprotinin reaU:nena on tbe helDOltatic ehanpa ud 
blood product roquitementa in 23 OLTa. 
MATERIALS AND METHODS 
In an open, proepective, and rudomized Itudy 23 ~tiente witb 
terminal liver diIeue (Table 1) underwent their flJ'lt OLT It tbe 
Univel"lity Hoepital Rudolf Vircbow, Berlin, Germany, betwNn No· 
vember 1989 and JUDe 1990. Tbe patienu were nmdomDed by aealed 
envelopee with aeria1 numbal'l contlininf the .Iy of IProtinin admin-
iltretioD. Thirteen patien&l wen thereby randomized to racelV'l Lv. boli 
oe 0.6 Mill KIU aprotin.i.D three tImee duriIi,. OLT, liven .t tbe 
berinninl of tbe operation, at tbe onMt o( tIM anbepatk pbue, and at 
tbe berinninr of reperfueion, .bereu 10 patiente were contin\JI:M1y 
treated with aprotinin mfulion (Tab!. 2). OL T .... cam.d out by 
Htablilhed 1UJ'lica1 techniquM uainc a vellOWlDOUl bypue (13, 14). 
P.cI,ed red blood ceJ.a (RBC) ud fnah frosen pla.une. (FFP) wera 
eubetituted to compenu.te for intra· and poRoperative blood 10M. 
PoatoperatiV'lIy, RBe concentra .... wert! pnerally liven .hen tbe 
bemOilobin concentraUon .... lower tban 9 &/dl, while FFP conctn-
tratea were admini.ttered wben tbe prottin concentration .... Iower 
than 6.0 &/dl. For cold .wrqe o( tbe pd liver, Beidr UW·CSS 
eolution (Dupont, Paria, France) .... UNd. 
8lood Mmplee _re taken from tbe arterialline; (1) aftar induction 
of aneatbeIia; (2) 6 min berore; e.od (3) 10 min alter the berinnina: of 
the ubepe.tic ltap. Fu.rtber Mmplee _re eoUected; (4) 6 lI1in before 
repedueiol'l ; (6) .. _U u 6 miI'I: (6) 16 min; (7) 60 miD; e.od (8) 12 br 
aftarwardl. In addition, a Mmple or the perfuute releued from tbe 
li"r pd vein durin, the nUlJUn, proc.dun witb uterial. blood .,u 
taken prior to openin( oe the hepatocaval anutolDOlii (P). Blood 
aampl .. weN collected in ptuÜc Iyrinpa prefdled with 1/ 10 volume of 
triaodium citrate. For the determination of t·p A activity uticoqulat.ed 
blood wu immed.i.etely acidified witb tcetate acid Another blood 
TAIILB 1. Chuacteriatice o( 23 patientll who underwent their first orthotopic liver transplantation wben aprotinin boli (B) or continuoUl 




Poatnecl'Otic cirrboaie 5 8 
Alcohol-toIic cirrhoait , 0 
Primary biliuy cirrhoaia 1 1 
Secondary biliary cirrhoeie (erythrohepatic proto- 1 0 
porphyrle) 
Budd Chiari Iyndrume I 0 
Liver cell carcinoma 1 0 
Metutatic Iiver • 1 
Total 13 I. 
TABLE 2. Aprotinin application UNd in 23 patientll who underwent 
their firat orthotopic liver tranaplantation 
Bolu.IfOVP 
0.6 Mill. KIU Induction o( aDeatheaia 
0.6 Mill. KIU Anhepatic phaae 
0.6 Mill. KIU Raperfuaion 
Skin doaure (heparin 260 
IU/hr) (heparin 500 IUf 
hr at&rtini 12 br After 
operation till the 3rd 
poatoperative day) 
Infuooion ........ P 
0.2 Mill. KIU/hr 
0.4 Mill. KIU/hr 
0.1 Mill. KIU/hr 
aample wu anticoagulated with a mature o( triaodium citratll, theo-
phyllin, adenoaine, and dipyridamol (or the determination o( plu min-
opn activator inhibitor (PAIl activity. Tbe epecimena were gently 
milled, centrifupd at 3000 Ufmin (or 20 min, and the aupernataot 
(ro:r.en at -70·C until meuurement. 
Tbe (ollowin, parametera wen meuured uaini oommereially avail-
.!Ible kib: protA;n C (PC) aetivity (Boehringer, MannlMim, Gnm. ny), 
antithrombin 111 (AT 111) ACtivity, pluminopn ACtivity, a t-antiplumin 
(a,-AP) activity, Cl-inhibitor (C1-inh) activity (all: Rehring Werke 
AG, MarbW'J, Germany), fibrinogen according to Clauaa (Hoffmann-
LaRoche, Baael Switierland). 1--PA and P AI activitiea wen determined 
by chromogenie eubetratll methoda, where .. t-PA antigen w .. me .. -
uNd Ulini a solid-phase enzyme immunouaay (alI: Kabi, Stockholm, 
Sweden). Thrombin-antithrombin III (TAT) compler.ea were deter-
mined by enzyme immunouaays (Behrinperke AG, Muburt, Ger-
many). Aprotinin w .. eltimated by ELiSA u previoWlly described 
(16). TEG oe reealcified wbole blood wu performed Uling a thromb-
elutolHph (HeUige, Fniburg, Germany). When whole-blood-c1ot lysis 
time (WBL T), tbe time between tbe maximal amplitude and complete 
lyait in tbe TEG, wu aborter tban 90 min, it wo denned .. aevere 
h)perfibrinolysia, and between 90 and 120 min, .. mild hyperfibrino-
lyail (8). 
StotwticaJ onaly,w. Uaing the M&rtinez and Iglewicz teilt (16), the 
dietribution oe the parameters Wal round t.o be abnormal. Thererore 
the nonparametric Mann-Whitney telt WH uaed to teilt the sirnifieance 
oe differenoea between grou~ . Values ror P<0.05 were oonaidered to 
be aignificant. 
RESULTS 
Median valuea of blood product requirementa during OLT 
were 8 (range: 4- 26) unita for RBC and 10.5 (7-35) unita for 
FFP in the bolus group and 7 (2- 20) unita for RBC and 8 (2-
28) unita for FFP in the infusion group. The difference wo not 
.ignificant. However, the UIe of RBC waa aignificantly lower 
(P-O.04Ö) in the infuaion group (median values (range): 3.5 (0-
9) unita [bolus groupJ); 1.5 (0--6) unita [infusion groupJ) in the 
Female M" 
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M~ I_' B B B I 
I , , , 50 (43-65) 49 (24~) 
3 0 I 0 49 (40--66) 
1 1 0 0 
" 
55 
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1 0 0 0 
" 1 0 0 0 50 
• 1 0 • 55 
8 6 5 • 47 (40-65) 53 (24--65) 
fint three postoperative daya alter the operation, whereas there 
waa no aignificant difference in FFP requiremente between tbe 
two groupa (6.5 (0-17J unita (infusion groupJö 9.5 (4-22) unita 
(bolus group) at the ume stage. Tbe median time o(intensive 
care in the bolus group wo 25 days (range: 14-58 days) 88 
compared with 23 dayB (11-36 daya) in the infusion group (NS). 
In TEG, hyperfibrinolysia waa stated in 7 out of 13 OLTs in 
the bolus group but ooly in 1 out of 10 OLTs in the infusion 
group (Fig. 1). Levels oft·PA activity increaaed in both groupa 
during the anhepatic phase, reaching their peaks immediately 
be(ore reperfusion. These muima, however, were significantly 
higher in the bolus group (Fig. 2). Tbe t-PA antigen levels in 
plaama did not differ between the two groups. In both groupa 
PAI levels increased alter reperfusion to comparablelevela (Fig. 
3). The cour&e of C1-inh did not differ for either group (Fig. 3). 
The levela of a2-AP were higher in the infusion group, reaching 
significance only 10 min after the beginning o( the anhepatic 
phaae and 12 hr alter reperfusion (Fig. 4). Plaaminogen concen-
tration ahowed no ditference in either group (Fig. 4). TAT 
complens showed significantly higher levels in the infusion 
group prior to the anhepatic phase and at ita oneet end alter 
reperfusion (Fig. 5), Similarly, fibrinogen levels were higher in 
the bolus groUp shortly before the anhepatic phaae and alter 
reperfusion (Fig. 5). The course o(PC and AT III activities did 
not differ in the two groupa (Fig. 6). Aprotinin levels were 
significantly higher in the infusion group (Fig. 7). 
In the perfusate the comparilOn of different hemostatic pa-
rameters betwe~m tbe groups revealed a aignificantly lower level 
oft-PA antigen and a tendentiously lower level in t-PA &etivity 
in the infusion group while activity o( the inhibitors PAI and 
a z-AP waa significantly increased in thia group. All otber pa-
rameten in the perfuaate were comperable in both groups 
(Table 3). 
D1SCUSSION 
Our previous e:rperience (1) prompted UI to postulate a 
beneficial effeet of aprotinin bolus application on the course of 
OLT, but signs of hyperfibrinolysis as meaaured by TEG Were 
.till preaent in most patienta undergoing OLT. Here, we have 
investigated the effeet o( intermittent bolus vereus continuous 
infusion application of aprotinin during the course of 23 OLTa 
in an open, prospective, and randomized study. 
We conrll'tDed previous inveetigations suggeating a beneficial 
effect of aprotinin bolus application in reducing signs of hyper-
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FIClUMr. 1. Sijl:na of hyperlibrinol)'si8 during orthotopic liver trans-
plantation in thromboelastogram in 13 patitnlll of 8protinin bolu8 
applicillion lind 10 pHlientll of Hprotinin infu.ion. 
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FIGUIH! 2. I· PA flct ivity and Rnligen during orthotopic livet Irlln8-
p]an\a\ion in ]3 plilienu of ap rOlinin bolus apllliclltion Ind 10 patientll 
of aprotinin infusion. 
Aprolinin levels were higher in the infusion group during the 
whole length of the ÜL Ts (Fig. 7). Signs o( hyperfibrinolysis. 
according to TEG and increased t ·PA aetivity (rigs. 1 and 2) 
oceurred more often in the bolus group especially before and 
after reperfusion, whereas PAI and a 2·A P levels (Figs. 3 and 4) 
were lower during the anhepatie phase and after reperfusion in 
the infusion group, respe<:tively. These results suggest that 
higher apfotinin levels maintained by continuou. infusion re· 
duee plasminogen activator aetivity in plasma and diminish 
signs of hyperfibrinolysis in the infusion group. 
After reperfusion a more pronounced inerease of TAT eorn· 
plexes and a coneomitant decrease of fibrinogen levels in the 
infusion group indieate an inereased prothrombin aetivation. 
Higher aprotinin levels may shift the hernostatic balance to· 
ward coagulation. As on the other hand aetivities of pe, AT 
111 , and CI · inh were nOl seriously decreased in either group no 
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FIGUME 3. PA l ltnd CI ·inhibitor IIc tiYit ies du ring orthotopic liyer 
tTl1ßsphtntlition in 13 plltienUi of aprotinin bolus application and 10 
plltienu of IIp rOlinin infUllion. 
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FIGUR": 4. Plasminogen ooncenwuion lind o" lIntiplalimin IIctiyity 
during orthotopic liver transplllntalion in 13 plltientl of aprotinin bolus 
IIpplicalion and 10 plltien13 of IIprotinin infusion. 
Dur results showed higher blood product requiremenlS during 
OLT in the bolus group but not to a significant level. All 23 
patienUJ sre still alive. and only one woman of the bolus group 
and one woman of the infusion group needed retransplantation 
because of seyere host·versus·graft resetioDs. Neither had he· 
patie artery thrombosis. Our preyious investigations of the 
perfu88te showed signifieantly higher TAT eomplexes and sig-
niricantly lower aetivities of the protease inhibitors pe, AT 111 , 
and CI · inh when compared with the systemic cireulation 5 min 
before reperfusion. This indieates increased prothrombin acti · 
vslion and a coDsumption of inhibitors in the graft liver (I). 
Furthermore. parameters of actiYAted phElgC)l:yteli such EIS elal ' 
tase and cathepsin 8 were found to be signifieantly eleyated in 
the perfusate (17). In addition, it hall recently Ileen demon· 
strßted that aprotinin exerts a protf!(:tive effect on ischemic 
hepatocellular damage oceurring in the rat liver.transplant 
model (/8). We wondered whether considering these results 
higher systemie leyels of aprotinin in the reperfusion phose wilJ 
• 
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FrGUElE 5. Thrombin antithrombin III complnel and fibrioopn 
concentration during orthotopic Iiver tran.plantation in 13 patienUi of 
Ilprotinin bolua application and 10 patient. of aprotinin infuJion. 
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FIGURE 6. Protein C and antithrombin III activities during ortho· 
topic liver traruplantation in 13 patienu of aprotinin bolus application 
and 10 patienta of aprotinin infusion. 
change hemoatatic parameters of the gratt liver perfuaate. 
Indeed, t-PA antigen and activity were lower and PAI and a2-
AP activitiea ware higher in tbe perfueate ofthe infusion group. 
In vitro atudies ahowed DO .ffeet ol different amount8 of aproti-
nin in t·PA end PA! activity assays (not publiahed). Presuming 
that hilh 8y1temic aprotinin levels lU'e mucin, endothelial 
damage in the flushed graft liver, the lower t·PA activity and 
antipn levela in the perfueate cu be nplained. In addition, it 
hu to be diecuued whether t-PA liberation is reduced by 
inhibition or kallikrein, a potent stimulator or t·PA release 
(19). However, the diminished t-PA releue in tbe graft liver 
did not resu1t in alower t·PA level in the aystemic circulation 
after reperfuaion. 
Parameten of thrombin formation and protease inhibiton 
did not differ in the perfueate and the syatemic circuJ.ation. 
In summary, aprotinin application by infusion resulte in 
sienificantly diminished signs of hyperiibrinolyais end a leuer 
inCnlue in t-PA activity intraoperatively. On the other band, 
! 
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FlOURE 7. Aprotinin concentrationa during orthotopic liver tran.-
planution in 13 patient. of aprotinin bolu. application and 10 patienta 
of aprotinin infwlion and P (bolue/infwlion) are demon.trated. 
TABLE 3. Comp.nltOn of different hemoetatic parameteR in the 
perfull8.te of 13 patienta in the bolue group u compared with 10 
patientl of the infwlion group who underwent their first 
orthotopic liver tr8l\.lplantation 
M.diaD (B) Ranp(B) P (BIl) median (I) ranp (I) 
t-PA activity (IU) I' 0.7-23.6 0.101 , 0.7-17.4 
t-PA antigen (nI/mI) 12.3 7.2-26.6 0.060 
10.1 1.2-19.3 
PAI activity (AU) 6.' 0-22 0.043 
17.8 8.8-30.4 






Fibrinocen (I/L) 1., 0-2.2 0.476 1.' 0-2.6 
TAT (mI/mi) 93.2 40.5-324 0.288 
73.5 32.5-1500 
pe(%) 9.' 0-2< 0.063 I' 3-50 AT III (%) 31 3-56 0.476 
37 9-55 
CI·inh (%) .. &-9' 0.254 
73 34- 109 
aprotinin given in higher concentrationB may influence the 
hemoatatic balance toward hypercoagulation. A beneficiaJ ef-
fect of aprotinin for the pnlvention of endothelial damage in 
the graft liver il auggelted. 
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